Published in AIDS Weekly, February 5th, 1996
The CPMP's decision was based on demonstrated proof of Zerit's clinical benefit in a randomized trial versus continued zidovudine (AZT). A definitive regulatory approval, valid in all 15 Member States (including Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden and the United Kingdom), is expected to be issued by the European Commission within the next three months.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.